ArticleDrug safety2022
Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance.
Article in Drug safety, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature.Pharmaceutical medicine · 2022Pooled it
- Pharmacovigilance Data From Digital Health Systems: Regulations, Implications, and Opportunities-A TransCelerate Perspective.Therapeutic innovation & regulatory science · 2026Article
- Does generative AI mean the "end of history" for pharmacovigilance automation? towards a framework for the future of human-AI systems.Frontiers in drug safety and regulation · 2026Article
- How is AI developing in pharmacovigilance?Therapeutic advances in drug safety · 2026Article
- Unlocking the potential: multimodal AI in biotechnology and digital medicine-economic impact and ethical challenges.NPJ digital medicine · 2025Review
- Might We Come Together on a Paradigm Shift to Manage ICSRs with a Decentralized Data Model?Drug safety · 2025Article
- Narrative Search Engine for Case Series Assessment Supported by Artificial Intelligence Query Suggestions.Drug safety · 2025Article
- Artificial Intelligence: Applications in Pharmacovigilance Signal Management.Pharmaceutical medicine · 2025Review
- Assessment of the Efficiency of a ChatGPT-Based Tool, MyGenAssist, in an Industry Pharmacovigilance Department for Case Documentation: Cross-Over Study.Journal of medical Internet research · 2025Article
- Performance and Reproducibility of Large Language Models in Named Entity Recognition: Considerations for the Use in Controlled Environments.Drug safety · 2025Article
- How LLMs can advance safety case intake-points to consider and insights from a proof of concept.Therapeutic advances in drug safety · 2025Review
- Pharmacovigilance - Technological Advancements, Recent Developments and Innovations.Current drug safety · 2025Review
- Trustworthy Artificial Intelligence in Dentistry: Learnings from the EU AI Act.Journal of dental research · 2024Review
- Digital Technology Applications in the Management of Adverse Drug Reactions: Bibliometric Analysis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Editorial: AI/ML in pharmacovigilance and pharmacoepidemiology.Frontiers in drug safety and regulation · 2024Article
- Governance of artificial intelligence and machine learning in pharmacovigilance: what works today and what more is needed?Therapeutic advances in drug safety · 2024Article
- Trustworthy AI for safe medicines.Nature reviews. Drug discovery · 2023Article
- Article
- A Science-Based Methodology Framework for the Assessment of Combination Safety Risks in Clinical Trials.Pharmaceutical medicine · 2023Article
- The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives.Drug design, development and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TransCelerate reports on the results of 2019, 2020, and 2021 member company (MC) surveys on the use of intelligent automation in pharmacovigilance processes. MCs increased the number and extent of implementation of intelligent automation solutions throughout Individual Case Safety Report (ICSR) processing, especially with rule-based automations such as robotic process automation, lookups, and workflows, moving from planning to piloting to implementation over the 3 survey years. Companies remain highly interested in other technologies such as machine learning (ML) and artificial intelligence, which can deliver a human-like interpretation of data and decision making rather than just automating tasks. Intelligent automation solutions are usually used in combination with more than one technology being used simultaneously for the same ICSR process step. Challenges to implementing intelligent automation solutions include finding/having appropriate training data for ML models and the need for harmonized regulatory guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.